Bausch Health Companies Inc
XMUN:BVF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bausch Health Companies Inc
XMUN:BVF
|
CA |
|
Tsogo Sun Ltd
F:G5E
|
ZA |
|
Kforce Inc
NYSE:KFRC
|
US |
|
NVR Inc
LSE:0NVR
|
US |
|
Draegerwerk AG & Co KGaA
F:DRW8
|
DE |
|
Energy Resources Of Australia Ltd
OTC:EGRAY
|
AU |
Bausch Health Companies Inc
Bausch Health Companies makes prescription medicines, over-the-counter products, and medical devices. Its products are aimed at areas like eye care, digestive health, skin conditions, and cosmetic or aesthetic treatments. It sells to patients through doctors, pharmacies, hospitals, and other healthcare providers, with a mix of branded drugs and niche medical products that are sold under its own names or through its subsidiaries. The company makes money mainly by selling prescription drugs, consumer health products, and devices. Some products are bought by pharmacies and wholesalers and then reached by patients through prescriptions or retail channels, while others are sold directly to healthcare providers. That gives Bausch Health a business model that combines pharmaceutical sales with medical device sales, rather than relying on just one type of product. What makes Bausch Health different is its focus on narrow, hard-to-replace healthcare categories where established brands and specialized treatments matter. It is not a broad drug giant selling across every therapy area; instead, it concentrates on specific health problems where doctors and patients often look for trusted, purpose-built products.
Bausch Health Companies makes prescription medicines, over-the-counter products, and medical devices. Its products are aimed at areas like eye care, digestive health, skin conditions, and cosmetic or aesthetic treatments. It sells to patients through doctors, pharmacies, hospitals, and other healthcare providers, with a mix of branded drugs and niche medical products that are sold under its own names or through its subsidiaries.
The company makes money mainly by selling prescription drugs, consumer health products, and devices. Some products are bought by pharmacies and wholesalers and then reached by patients through prescriptions or retail channels, while others are sold directly to healthcare providers. That gives Bausch Health a business model that combines pharmaceutical sales with medical device sales, rather than relying on just one type of product.
What makes Bausch Health different is its focus on narrow, hard-to-replace healthcare categories where established brands and specialized treatments matter. It is not a broad drug giant selling across every therapy area; instead, it concentrates on specific health problems where doctors and patients often look for trusted, purpose-built products.
Strong quarter: Bausch Health, excluding Bausch & Lomb, said it delivered its 12th straight quarter of year-over-year revenue and adjusted EBITDA growth, with first-quarter revenue up 14% and adjusted EBITDA up 17%.
Salix led: Salix had an “outstanding quarter,” with revenue up 18% as Xifaxan continued to grow on stronger volume, net pricing, and some lingering Medicaid channel effects.
Solta surged: Solta posted very strong growth, especially in China, where revenue rose 193% and management said demand remained robust after the Shibo acquisition.
Guidance held: Full-year 2026 guidance was reaffirmed, and management said the outlook already includes the expected impact of new pharma tariffs effective in late September 2026.
Balance sheet: The company said it reduced net debt by more than $100 million in the quarter, after finishing the remaining U.S. opt-out litigation payments.
Pipeline focus: Management highlighted progress on larsucosterol, broader indication work, and a disciplined approach to business development, while saying equity is not a priority funding option right now.
